At Smith+Nephew, we design and make technology that takes the limits off living, and we help healthcare professionals achieve the same goal. Together we improve life, while also improving performance.
We are a constituent of the UK’s FTSE100 and our shares are traded on the London Stock Exchange and through American Depository Receipts on the New York Stock Exchange (LSE: SN, NYSE: SNN)
Life Unlimited. Smith+Nephew exists to restore people’s bodies and their self-belief.
A successful business needs to have a purpose-driven culture. Our culture pillars guide our behaviours and build a winning spirit.
A culture of empathy and understanding for each other, our customers and patients.
A culture of teamwork based on mutual trust and respect.
A culture of continuous learning, innovation and accountability.
Five new strategic imperatives form our value creation plan for the medium term.
Orthopaedics includes an innovative range of Hip and Knee Implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and Trauma products used to stabilise severe fractures and correct bone deformities.
Our Sports Medicine and Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. They operate in growing markets where unmet clinical needs provide opportunities for procedural and technological innovation.
Our Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, to help healthcare professionals get CLOSER TO ZERO human and economic consequences of wounds.